These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30030604)

  • 21. Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry.
    Fauchier L; Greenlaw N; Ferrari R; Ford I; Fox KM; Tardif JC; Tendera M; Steg PG;
    PLoS One; 2015; 10(4):e0125164. PubMed ID: 25915904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study.
    Lamberts M; Gislason GH; Lip GY; Lassen JF; Olesen JB; Mikkelsen AP; Sørensen R; Køber L; Torp-Pedersen C; Hansen ML
    Circulation; 2014 Apr; 129(15):1577-85. PubMed ID: 24470482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of on-treatment platelet reactivity between triple antiplatelet therapy with cilostazol and standard dual antiplatelet therapy in patients undergoing coronary interventions: a meta-analysis.
    Panchal HB; Shah T; Patel P; Albalbissi K; Molnar J; Coffey B; Khosla S; Ramu V
    J Cardiovasc Pharmacol Ther; 2013 Nov; 18(6):533-43. PubMed ID: 23872509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Duration of Dual Antiplatelet Therapy in Coronary Artery Disease: a Review Article.
    Moseley AD; Collado FM; Volgman AS; Schaer GL; Snell RJ
    Curr Atheroscler Rep; 2016 Jul; 18(7):45. PubMed ID: 27260146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (ÖGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC).
    Korte W; Cattaneo M; Chassot PG; Eichinger S; von Heymann C; Hofmann N; Rickli H; Spannagl M; Ziegler B; Verheugt F; Huber K
    Thromb Haemost; 2011 May; 105(5):743-9. PubMed ID: 21437351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining antiplatelet and anticoagulant therapies.
    Holmes DR; Kereiakes DJ; Kleiman NS; Moliterno DJ; Patti G; Grines CL
    J Am Coll Cardiol; 2009 Jul; 54(2):95-109. PubMed ID: 19573725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes.
    Serebruany VL; DiNicolantonio JJ
    Thromb Haemost; 2013 Jul; 110(1):5-10. PubMed ID: 23743577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modern antiplatelet agents in coronary artery disease.
    Power RF; Hynes BG; Moran D; Yagoub H; Kiernan G; Ruggiero NJ; Kiernan TJ
    Expert Rev Cardiovasc Ther; 2012 Oct; 10(10):1261-72. PubMed ID: 23190065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of Different β-Blockers on Platelet Aggregation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy.
    Ignjatovic V; Pavlovic S; Miloradovic V; Andjelkovic N; Davidovic G; Djurdjevic P; Stolic R; Iric-Cupic V; Simic I; Ignjatovic VD; Petrovic N; Smiljanic Z; Zdravkovic V; Simovic S; Jovanovic D; Nesic J
    J Cardiovasc Pharmacol Ther; 2016 Jan; 21(1):44-52. PubMed ID: 25868659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pretreatment with antiplatelet drugs in invasively managed patients with coronary artery disease in the contemporary era: review of the evidence and practice guidelines.
    Capodanno D; Angiolillo DJ
    Circ Cardiovasc Interv; 2015 Mar; 8(3):e002301. PubMed ID: 25717045
    [No Abstract]   [Full Text] [Related]  

  • 31. Antiplatelet and Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Coronary Stenting.
    Dzeshka MS; Brown RA; Capodanno D; Lip GY
    Interv Cardiol Clin; 2017 Jan; 6(1):91-117. PubMed ID: 27886825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual antiplatelet therapy use by Canadian cardiac surgeons.
    Yanagawa B; Ruel M; Bonneau C; Lee MM; Chung J; Al Shouli S; Fagan A; Al Khalifa A; White CW; Yamashita MH; Currie ME; Teoh H; Mewhort HE; Verma S
    J Thorac Cardiovasc Surg; 2015 Dec; 150(6):1548-54.e3. PubMed ID: 26395051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New antiplatelet agents in the acute stage of coronary artery disease].
    Chatot M; Schiele F
    Rev Prat; 2015 Mar; 65(3):339-40. PubMed ID: 26016191
    [No Abstract]   [Full Text] [Related]  

  • 34. Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: A preliminary report.
    Chyrchel B; Totoń-Żurańska J; Kruszelnicka O; Chyrchel M; Mielecki W; Kołton-Wróż M; Wołkow P; Surdacki A
    Platelets; 2015; 26(6):593-7. PubMed ID: 25350775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study.
    Gajos G; Rostoff P; Undas A; Piwowarska W
    J Am Coll Cardiol; 2010 Apr; 55(16):1671-8. PubMed ID: 20394870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Platelet aggregation and antiplatelet agents in acute coronary syndromes].
    Collet JP; Choussat R; Montalescot G
    Med Sci (Paris); 2004 Mar; 20(3):291-7. PubMed ID: 15067573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
    Pareek M; Bhatt DL; Ten Berg JM; Kristensen SD; Grove EL
    Expert Opin Pharmacother; 2017 Jun; 18(9):875-883. PubMed ID: 28489475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antithrombotics in atrial fibrillation and coronary disease.
    Velagapudi P; Turagam MK; Agrawal H; Mittal M; Kocheril AG; Aggarwal K
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):977-86. PubMed ID: 25046150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response to letter regarding article, "Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease".
    Fujisue K; Sugiyama S; Ono T; Matsuzawa Y; Akiyama E; Sugamura K; Matsubara J; Kurokawa H; Kaikita K; Iwashita S; Sumida H; Hokimoto S; Oniki K; Nakagawa K; Matsui K; Ogawa H
    Circ Cardiovasc Interv; 2013 Oct; 6(5):e66. PubMed ID: 24129939
    [No Abstract]   [Full Text] [Related]  

  • 40. Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable patients with CAD treated with dual ANtiplatelet therapy) study.
    Pelliccia F; Greco C; Gaudio C; Rosano G; Vitale C; Marazzi G; Rollini F; Angiolillo DJ
    J Thromb Thrombolysis; 2015 Oct; 40(3):331-9. PubMed ID: 25761430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.